Wire · opportunities
Roche Holding (SWX:ROP) Gets Phase III Win And FDA Priority Review For Two Drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 September 2026 · Fusion42 review
Roche's collaborator MediLink reported positive Phase III results for Tam-Peli in relapsed small-cell lung cancer, showing significant survival benefits. Genentech, Roche’s US unit, received FDA Priority Review for Enspryng to treat MOGAD, a rare autoimmune disease with no approved therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a narrower opportunity window as FDA fast tracks Roche’s rare disease drug, making early positioning vital in autoimmune treatment. Oncology drugmakers must prepare for higher competition from Roche’s promising Tam-Peli survival gains.
◆ Coverage
1 source · 13 Sep 2026
◆ Related on Wire
◆ Topics